GeneNews in pact for first personalized medicine center in China
February 6, 2012 by Jennifer Poland · Leave a Comment
GeneNews (TSX:GEN) has signed a memorandum of understanding with Shanghai Biochip, a leading Chinese engineering center for advanced microarray and gene expression profiling technologies, for a strategic alliance to establish the first Sentinel Centre for Personalized Medicine in China. GeneNews and SBC would jointly establish and manage the Sentinel Centre for Personalized Medicine to co-develop [...]
GeneNews platform identifies blood biomarkers for NPC
November 10, 2011 by leonardzehr · Leave a Comment
In a presentation at the 2011 Asia Pacific Cancer Conference, GeneNews (TSX:GEN) reported that a study using its proprietary Sentinel Principle platform technology identified blood-based biomarkers that distinguished nasopharyngeal carcinoma (NPC) patients from controls and from patients with other cancers with high accuracy. NPC is a common cancer in certain parts of Northern Africa and [...]
GeneNews launches ColonSentry in Malaysia
November 9, 2011 by leonardzehr · Leave a Comment
GeneNews (TSX:GEN) has announced the commercial launch of ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer, in Malaysia through its GeneNews Diagnostics Sdn. Bhd. subsidiary. “We are excited that GeneNews Diagnostics will now be able to provide the Malaysian population with access to this potentially life-saving colorectal cancer [...]
GeneNews holders okay stock consolidation
October 31, 2011 by stephenkilmer · Leave a Comment
Shareholders of GeneNews (TSX:GEN) at a special meeting approved a proposed share consolidation of the basis of one post-consolidation common share for every six pre-consolidation common shares. The timing for implementation of the consolidation will be determined by the company’s board of directors, but will be no later than Jan. 31, 2012. “We believe that [...]
Schizophrenia biomarkers found by GeneNews’ Sentinel Principle
October 14, 2011 by leonardzehr · Leave a Comment
A study using GeneNews’ (TSX:GEN) Sentinel Principle platform technology to identify complex changes in blood gene expression patterns that may be indicative of underlying risk factors for schizophrenia will be published in the American Journal of Medical Genetics Part B and is currently available online. “This study shows that we can identify a gene signature [...]
GeneNews technology able to predict risk of liver cancer for patients with chronic hepatitis
July 15, 2011 by leonardzehr · Leave a Comment
A poster entitled “Biomarkers to predict risk of subsequent hepatocellular cancer in patients with chronic hepatitis,” describing the initial phase of analysis of a 1,600-cohort study using GeneNews’ (TSX:GEN) Sentinel Principle, was presented at the 9th Liver Update 2011 conference in Malaysia. The poster reports on the application of the Sentinel Principle platform technology to [...]
GeneNews closes warrant exercise incentive program
June 9, 2011 by leonardzehr · Leave a Comment
GeneNews (TSX:GEN) has completed an early warrant exercise incentive program and debenture conversion, raising almost $3 million. A total of 74% of eligible warrants were exercised and the company issued 12.8 million common shares and 12.8 million incentive warrants. In addition, holders of 25% of eligible convertible debentures participated in the debenture conversion, resulting in [...]
Prescription for growth
November 23, 2010 by leonardzehr · Leave a Comment
We, at biotuesdays.com, attended Dundee Capital Markets’ second emerging growth conference last week, where over 20 technology, life sciences and industrial growth companies presented. Dundee specializes in early-stage growth, and to say that the one-day showcase was jammed full of investment ideas is a bit of understatement. Here’s a sampling of what we took away [...]
GeneNews gets Malaysian seed grant
November 2, 2010 by stephenkilmer · Leave a Comment
GeneNews (TSX:GEN) has received approval of a seed capital grant of about $625,000 from the Malaysian Biotechnology Corp. to support the commercial launch of its ColonSentry, the world’s first blood-based test to determine a person’s current risk for colorectal cancer, in Malaysia. “Driving the global commercialization and clinical adoption of the ColonSentry test as an [...]
You asked a CEO
October 4, 2010 by leonardzehr · Leave a Comment
Four weeks ago, we asked you what’s on your mind. Specifically, what would you like to “Ask a CEO?” Frankly, we were heartened and surprised by your response. So as promised, this week’s Feature, which coincides with the first anniversary of biotuesdays.com’s launch, is a rundown of the questions and the answers we received. We [...]



